Apremilast (Otezla®)

Assessment Status NCPE Assessment Process Complete
Drug Apremilast
Brand Otezla®
Indication For moderate to severe chronic plaque psoriasis.
Assessment Process
Rapid review commissioned 24/02/2015
Rapid review completed 03/04/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 28/07/2015
NCPE assessment completed 27/01/2016
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.